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Abstract: BACKGROUND Sepsis and septic shock are severe inflammatory conditions related to high
morbidity and mortality. We performed a systematic review with meta-analysis of randomized trials to
assess whether extracorporeal blood purification reduces mortality in this setting. METHODS Electronic
databases were searched for pertinent studies up to January 2019. We included randomized controlled
trials on the use of hemoperfusion, hemofiltration without a renal replacement purpose, and plasmaphere-
sis as a blood purification technique in comparison to conventional therapy in adult patients with sepsis
and septic shock. The primary outcome was mortality at the longest follow-up available. We calculated
relative risks and 95% CIs. The grading of recommendations assessment, development and evaluation
methodology for the certainty of evidence was used. RESULTS Thirty-seven trials with 2,499 patients
were included in the meta-analysis. Hemoperfusion was associated with lower mortality compared to
conventional therapy (relative risk = 0.88 [95% CI, 0.78 to 0.98], P = 0.02, very low certainty evidence).
Low risk of bias trials on polymyxin B immobilized filter hemoperfusion showed no mortality difference
versus control (relative risk = 1.14 [95% CI, 0.96 to 1.36], P = 0.12, moderate certainty evidence), while
recent trials found an increased mortality (relative risk = 1.22 [95% CI, 1.03 to 1.45], P = 0.02, low
certainty evidence); trials performed in the United States and Europe had no significant difference in
mortality (relative risk = 1.13 [95% CI, 0.96 to 1.34], P = 0.15), while trials performed in Asia had a
positive treatment effect (relative risk = 0.57 [95% CI, 0.47 to 0.69], P < 0.001). Hemofiltration (relative
risk = 0.79 [95% CI, 0.63 to 1.00], P = 0.05, very low certainty evidence) and plasmapheresis (rela-
tive risk = 0.63 [95% CI, 0.42 to 0.96], P = 0.03, very low certainty evidence) were associated with a
lower mortality. CONCLUSIONS Very low-quality randomized evidence demonstrates that the use of
hemoperfusion, hemofiltration, or plasmapheresis may reduce mortality in sepsis or septic shock. Existing
evidence of moderate quality and certainty does not provide any support for a difference in mortality
using polymyxin B hemoperfusion. Further high-quality randomized trials are needed before systematic
implementation of these therapies in clinical practice.
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ABSTRACT
Background: Sepsis and septic shock are severe inflammatory conditions 
related to high morbidity and mortality. We performed a systematic review with 
meta-analysis of randomized trials to assess whether extracorporeal blood 
purification reduces mortality in this setting.
Methods: Electronic databases were searched for pertinent studies up to 
January 2019. We included randomized controlled trials on the use of hemo-
perfusion, hemofiltration without a renal replacement purpose, and plasma-
pheresis as a blood purification technique in comparison to conventional 
therapy in adult patients with sepsis and septic shock. The primary outcome 
was mortality at the longest follow-up available. We calculated relative risks 
and 95% CIs. The grading of recommendations assessment, development and 
evaluation methodology for the certainty of evidence was used.
Results: Thirty-seven trials with 2,499 patients were included in the 
meta-analysis. Hemoperfusion was associated with lower mortality compared 
to conventional therapy (relative risk = 0.88 [95% CI, 0.78 to 0.98], P = 0.02, 
very low certainty evidence). Low risk of bias trials on polymyxin B immobilized 
filter hemoperfusion showed no mortality difference versus control (relative 
risk = 1.14 [95% CI, 0.96 to 1.36], P = 0.12, moderate certainty evidence), 
while recent trials found an increased mortality (relative risk = 1.22 [95% 
CI, 1.03 to 1.45], P = 0.02, low certainty evidence); trials performed in the 
United States and Europe had no significant difference in mortality (relative 
risk = 1.13 [95% CI, 0.96 to 1.34], P = 0.15), while trials performed in Asia 
had a positive treatment effect (relative risk = 0.57 [95% CI, 0.47 to 0.69], 
P < 0.001). Hemofiltration (relative risk = 0.79 [95% CI, 0.63 to 1.00], 
P = 0.05, very low certainty evidence) and plasmapheresis (relative risk = 
0.63 [95% CI, 0.42 to 0.96], P = 0.03, very low certainty evidence) were 
associated with a lower mortality.
Conclusions: Very low-quality randomized evidence demonstrates that the 
use of hemoperfusion, hemofiltration, or plasmapheresis may reduce mortality 
in sepsis or septic shock. Existing evidence of moderate quality and certainty 
does not provide any support for a difference in mortality using polymyxin 
B hemoperfusion. Further high-quality randomized trials are needed before 
systematic implementation of these therapies in clinical practice.
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Today, sepsis remains one of the main causes of mor-bidity and mortality in the intensive care unit. Despite 
recent advancement in intensive care unit and sepsis man-
agement, mortality still remains high.1–4
The pathogenesis of sepsis involves many complex cel-
lular and biochemical interactions between leukocytes, 
platelets, endothelial cells, and the complement system that 
trigger an inflammatory response.5 Inflammation is caused 
by the production of pro- and antiinflammatory mediators, 
such as cytokines, in the presence of infection and/or bac-
terial toxins, and the imbalance between these mediators or 
their excessive production may lead to multiorgan failure 
due to a prolonged or inadequate systemic inflammatory 
response syndrome.5,6
Extracorporeal blood purification techniques have been 
proposed as adjunctive therapy in sepsis. These techniques 
are based on the principle that removal and modulation 
of blood pro- and antiinflammatory mediators or bacterial 
toxins (or both) could attenuate the sepsis-related massive 
EDITOR’S PERSPECTIVE
What We Already Know about this topic
• Among patients with sepsis or septic shock, a variety of extracorpo-
real blood purification techniques are available
• Individual existing trials evaluating these options are underpowered 
to provide clear evidence
What this Article tells Us that Is New
• Meta-analysis of very low-quality randomized controlled trial evi-
dence demonstrates a potential benefit of hemoperfusion, hemofil-
tration, or plasmapheresis
• Additional high-quality trials demonstrating benefit in modern clini-
cal practice are needed before recommending these therapies
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systemic inflammatory response, reducing morbidity and 
mortality.7,8 Several different extracorporeal techniques 
have been studied for this purpose.
Hemoperfusion involves the placement of a sorbent 
cartridge in direct contact with blood via an extracorpo-
real circuit. The removal characteristics of hemoperfusion 
are dependent on the different types of sorbent used and 
could also target high-molecular-weight molecules, usu-
ally not captured by conventional hemofilters. The most 
studied therapy is polymyxin B immobilized fiber column 
hemoperfusion with Toraymyxin (Toray Industries Ltd., 
Japan),  that could capture circulating bacterial endotoxin9 
and modulate the inflammatory response.10 Another device 
is the CytoSorb (CytoSorbents Corporation, USA), a novel 
filter potentially able to remove both pro-inflammatory and 
antiinflammatory cytokines.11
Renal replacement devices such as hemofiltration or 
hemodiafiltration could be used to remove part of the 
inflammatory mediators and toxins in septic patients with-
out renal indication for kidney replacement therapy, by 
employing standard or special filters with adsorptive prop-
erties.12 Limited data are available on plasmapheresis, a tech-
nique based on plasma replacement with fresh frozen plasma 
or albumin,12 that has the potential to remove inflammatory 
cytokines and restore deficient plasma proteins.
Despite the large number of available techniques, actual 
evidence is scarce, and these therapies have not entered 
into daily clinical practice around the world yet. Several 
small trials were published on various devices, and the most 
comprehensive meta-analysis summarizing the evidence 
on blood purification is outdated.13 Some more recent 
meta-analyses focusing on polymyxin B immobilized 
fiber column hemoperfusion14,15 or hemofiltration16 did 
not include some relevant trials nor the final results of the 
largest randomized study performed on the topic so far.17 
Therefore, we performed a meta-analysis of randomized 
control trials in order to determine whether extracorporeal 
blood purification decreased mortality in patients with sep-
sis and septic shock.
Materials and Methods
The current systematic review was conducted in com-
pliance with the PRISMA (Preferred Reporting Items 
Systematic Reviews and Meta-Analysis) guidelines18 
(Supplemental Digital Content, table S1, http://links.
lww.com/ALN/B977) and Cochrane methodology19 and 
according to a prepublished protocol (PROSPERO data-
base, CRD42018104643).
Search Strategy
Two investigators (A.P. and R.S.) independently searched 
PubMed, the Cochrane Central Register of clinical tri-
als, and Embase up to January 1, 2019, for relevant articles 
(Supplemental Digital Content, table S2, http://links.lww.
com/ALN/B977). The search strategy aimed to include any 
randomized study performed with any type of extracorpo-
real blood purification technique compared to conventional 
therapy in adult critically ill patients with sepsis and septic 
shock. Abstracts from recent international conferences were 
searched for additional studies. In addition, we hand-scanned 
references of retrieved articles and pertinent reviews to iden-
tify other eligible trials (backward snowballing).
Study Selection
References obtained from searches were first independently 
examined at the abstract level by two authors (A.P. and 
R.S.) and then collected as full-text articles if potentially 
relevant. Eligible studies met the following PICOS criteria: 
(1) Population: adult critically ill patients with sepsis with or 
without septic shock; (2) Intervention: any extracorporeal 
blood purification technique (hemoperfusion, renal replace-
ment therapy techniques, plasmapheresis); (3) Comparison 
intervention: conventional therapy; (4) Outcome: mor-
tality at longest follow-up available; and (5) Study design: 
randomized controlled trial. The exclusion criteria were 
blood purification for renal failure indication at randomiza-
tion, trials with overlapping populations with a previously 
included article (e.g., manuscripts with different follow-up 
or subanalyses of a previously published trial), and pediatric 
studies. Two authors (A.P. and R.S.) independently assessed 
selected studies for the final analysis, with disagreements 
resolved by consensus with a third author (G.L.). If the arti-
cle did not include data on mortality or was not full-text, 
the corresponding author was contacted for further data. 
No language restrictions were imposed.
Data Abstraction
One author (A.P.) extracted relevant information from each 
selected study. These data were checked by another author 
(R.S.). Disagreement was resolved by consensus with a third 
author (G.L.). We specifically extracted potential sources of 
significant clinical heterogeneity (e.g., study design, clinical 
setting, inclusion and exclusion criteria, blood purification 
regimen).
The primary endpoint of this review was mortality at 
the longest follow-up available, and the secondary endpoint 
was mortality at 28 to 30 days.
Quality Assessment
Two authors (A.P. and R.S.) independently assessed the 
internal validity of each included trial according to the 
Cochrane Collaboration methods.19,20 We assessed the 
risk of bias associated with the random sequence genera-
tion, allocation concealment, blinding of participants and 
personnel, blinding of outcome assessment, complete-
ness of outcome data, selective reporting, and other bias. 
The other bias domain included the classic items reported 
by the “Cochrane Handbook for Systematic Reviews of 
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Interventions”19 but also the presence of an intention-to-
treat analysis, sample size calculation, and ethical approval 
of the trial. If one or more of the domains were judged 
as having a high or unclear risk of bias, we classified the 
trial as having a high risk of bias. Due to the nature of the 
intervention, blinding of participants and personnel seemed 
difficult and was therefore not judged as crucial for bias 
assessment. We evaluated the potential risk of bias by apply-
ing a rating of “Low,” “High,” or “Unclear” to each study.
Two authors (A.P. and R.S.) independently reviewed 
the presence of authors’ possible conflict of interest and the 
funding source for each study, then rated each trial as of 
“Low,” “High,” or “Unclear” risk regarding those specific 
points.
The certainty of the body of evidence was assessed using 
the grading of recommendations assessment, development, 
and evaluation framework.21,22 The grading of recommen-
dations assessment, development, and evaluation framework 
characterizes the certainty of a body of evidence on the 
basis of study limitations, imprecision, inconsistency, indi-
rectness, and other considerations.
Statistical Analysis
Individual trial and summary results were reported as rel-
ative risk with 95% CI. We used a random-effects model 
except in cases where few trials dominated the available 
evidence or where significant publication bias was present, 
as random-effects meta-analysis applied in these contexts 
may give inappropriately high weight to smaller studies. 
Statistical heterogeneity was explored by the Cochran Q sta-
tistic and characterized using the I2 metric. Publication bias 
was assessed by visually inspecting the funnel plot for the 
primary outcome. Statistical significance was set at P = 0.05. 
The meta-analysis was performed using Review Manager 
(RevMan, version 5.3; The Nordic Cochrane Center, The 
Cochrane Collaboration, Copenhagen, Denmark, 2014).
The primary analysis was stratified by blood purifica-
tion technique: hemoperfusion, hemofiltration, hemoper-
fusion combined with hemofiltration, or plasmapheresis. 
Hemoperfusion subgroup analyses including trials on poly-
myxin B immobilized fiber column hemoperfusion or 
hemoperfusion with other devices were carried out. To 
explore the sources of heterogeneity, we performed some 
subgroup analyses: (1) low risk of bias versus unclear/high 
risk of bias trials; (2) trials conducted in Asia versus Europe 
and America; (3) trials from the Nakamura group versus other 
trials; and (4) trials published after 2010 versus older trials.
To explore the relationship between treatment effect 
and disease severity, we performed various analyses: (1) a 
random-effects meta-regression on the APACHE II (Acute 
Physiology, Age, Chronic Health Evaluation II) score,23 
sepsis-related organ failure assessment score,24 and control 
group mortality;14 (2) subgroup analyses according to con-
ventional therapy group mortality: low-risk group (mor-
tality rate less than 30%), intermediate-risk group (30 to 
60%), and high-risk group (greater than 60%).14 We also 
performed a meta-regression for age to investigate a possi-
ble influence on outcome estimates. Finally, sensitivity anal-
yses were performed by analyzing the data with a fixed or 
random effects model and using other summary statistics.
We performed a predefined random-effects trial sequen-
tial analysis,25–27 with the intent of maintaining an overall 
5% risk of type I error and a 10% risk of type II error. 
We assumed a relative risk reduction of 15% and derived 
the control event proportion from the actual dataset. The 
resulting required information size was further diversity 
(D2)-adjusted. In case of D2 = 0 we performed a sensitivity 
analysis assuming a D2 = 25%. We used the trial sequential 
analysis software (TSA Viewer [Computer program], version 
0.9.5.5 Beta, Copenhagen Trial Unit, Center for Clinical 
Intervention Research, Rigshospitalet, Copenhagen, 
Denmark, 2016). Deviations from the initial protocol are 
reported in the supplement (Supplemental Digital Content, 
eMethods 1, http://links.lww.com/ALN/B977).
Results
Search results and Study Characteristics
The search strategy identified 6,933 citations and, after 
exclusion of inadequate reports (Supplemental Digital 
Content, table S3, http://links.lww.com/ALN/B977), 37 
trials with 2,499 patients were included in the meta-analy-
sis (fig. 1).17,28–63
The characteristics of the included studies are shown in 
table 1 and in the supplement (Supplemental Digital Content, 
tables S4-S6, http://links.lww.com/ALN/B977). Two trials 
had four treatment arms.43,58 Twenty trials used a hemoperfu-
sion technique, 13 used hemofiltration or hemodiafiltration, 
4 trials combined hemofiltration with hemoperfusion, and 2 
trials used plasma exchange. In three cases we received fur-
ther information from corresponding authors.17,59,62
Three trials were judged to be at low risk of bias,17,30,46 
20 at unclear risk, and 14 at high risk (Supplemental Digital 
Content, figs. S1 and S2, http://links.lww.com/ALN/
B977). The grading of recommendations assessment, devel-
opment, and evaluation assessment is reported in table S7 in 
the Supplemental Digital Content (http://links.lww.com/
ALN/B977).
Hemoperfusion techniques
Hemoperfusion (20 trials and 1,548 patients), which com-
prises various techniques differing among other things on 
the presence or absence of polymyxin B in the treatment 
regimen, was associated with a lower mortality compared to 
the control group (relative risk = 0.87 [95% CI, 0.78 to 0.98], 
P = 0.02, trial sequential analysis inconclusive, very low-cer-
tainty evidence) the analysis was limited by publication bias, 
small trial effects, and high heterogeneity (Supplemental 
Digital Content, figs S3-S5 and table S8, http://links.
lww.com/ALN/B977). Subanalyses are reported in the 
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supplement (Supplemental Digital Content, figs. S6—S9 and 
eResults 1, http://links.lww.com/ALN/B977).
Polymyxin B Immobilized Fiber Column Hemoperfusion. 
Polymyxin B immobilized fiber column hemoperfusion (13 
trials and 1,163 patients) was associated with a lower mor-
tality at longest follow-up available compared to control 
(relative risk = 0.87 [95% CI, 0.77 to 0.98], P = 0.03, very 
low-certainty evidence), although the analysis was limited 
by very high heterogeneity (I2 = 74%, P
heterogeneity
 < 0.001) 
(fig. 2). No significant difference in 30-day mortality was 
found (Supplemental Digital Content, fig. S9, http://links.
lww.com/ALN/B977).
Low risk of bias trials (three trials and 745 patients) 
found no difference in mortality with polymyxin B 
immobilized fiber column hemoperfusion versus control 
(relative risk  =  1.14 [95% CI, 0.96 to 1.36], P  =  0.12, 
moderate-certainty evidence; fig.  2). Recent trials pub-
lished after 2010 (three trials and 740 patients) showed 
that polymyxin B immobilized fiber column hemoper-
fusion was associated with higher mortality than con-
ventional therapy (relative risk  =  1.22 [95% CI, 1.03 to 
1.45], P = 0.02, I2 = 0%, low-certainty evidence), while 
trials published before 2011 were associated with a mor-
tality benefit (relative risk = 0.58 [95% CI, 0.49 to 0.69], 
P < 0.001, I2 = 8%; P
groups
 < 0.001). Studies conducted in 
Asia (seven trials in Japan and one in Thailand, with a total 
of 367 patients) showed that polymyxin B immobilized 
fiber column hemoperfusion decreased mortality (relative 
risk = 0.62 [95% CI, 0.52 to 0.75], P < 0.001, I2 = 57%, 
P
heterogeneity
  =  0.02), while aggregate data from trials con-
ducted in the United States and Europe (five trials and 796 
Fig. 1. Flow diagram for the selection of studies. prISmA, preferred reporting Items Systematic reviews and meta-Analysis.
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polymyxin b–immobilized filter column hemoperfusion
 Cantaluppi 2008 Italy 16 Sepsis with positive culture for Gram- 
negative bacteria
pmX-Hp 2 sessions of 2 h at 24-h 
interval
38% Unclear
 Cruz 2009 Italy 64 Severe sepsis or septic shock from an 
abdominal source
pmX-Hp 2 sessions of 2 h at 24-h 
interval
67% Low
 Dellinger 2018 USA and 
Canada
449 Septic shock and an high endotoxin activity 
assay level
pmX-Hp 2 sessions of 2 h at 24-h 
interval
42% Low
 Nakamura 1999 Japan 50 Septic shock pmX-Hp 2 sessions of 2 h at 24-h 
distance
70% Unclear
 Nakamura 2002(a) Japan 18 Sepsis and trauma pmX-Hp 2 sessions of 2 h at 24-h 
interval
78% Unclear
 Nakamura 2002(b) Japan 14 Sepsis pmX-Hp 2 sessions of 2 h at 24-h 
interval
86% Unclear
 Nakamura 2003(a) Japan 20 Sepsis and mrSA-associated 
glomerulonephritis
pmX-Hp 2 sessions of 2 h at 24-h 
interval
80% Unclear
 Nakamura 2003(b) Japan 60 mrSA sepsis pmX-Hp 2 sessions of 2 h at 24-h 
interval
64% Unclear
 Nemoto 2001 Japan 98 Sepsis, severe sepsis, or septic shock pmX-Hp 1 or 2 sessions of 4 h 89% Unclear
 payen 2015 France 232 Septic shock from and abdominal source pmX-Hp 2 sessions of 1.5 h at 
22–24-h interval
24% Low
 Srisawat 2018 thailand 59 Severe sepsis or septic shock, high endo-
toxin activity assay level, mostly under 
renal replacement therapy
pmX-Hp 2 sessions of 2 h at 24-h 
interval
50% High
 Suzuki 2002 Japan 48 Septic shock pmX-Hp 1 Hp session of 4 h, then 
1 CVVHDF session until 
24 h
75% Unclear
 Vincent 2005 europe 35 Severe sepsis or septic shock from an 
intraabdominal source
pmX-Hp 1 session of 2 h 28% Unclear
Other hemoperfusion devices
 Hawchar 2019 Hungary 20 Septic shock of medical origin Hp with CytoSorb 1 session of 24 h 20% High
 Huang 2010 China 44 Severe sepsis or septic shock Hp with HA330 resin 
cartridge (Lizhu 
Industries, China)
3 sessions of 2 h at 24-h 
interval
55% Unclear
 Huang 2013 China 46 Severe sepsis or septic shock with acute 
lung injury from extrapulmonary source
Hp with HA330 resin 
cartridge
3 sessions of 2 h at 24-h 
interval
67% High






A daily session for the 
first 4 d
25% High
 Scha﻿̈dler 2017 Germany 97 Severe sepsis or septic shock and ALI/ 
ArDS
Hp with CytoSorb 1 daily session of 6 h up 
to 7 d
26% High
 Shum 2014 China 15 Septic shock from an intra-abdominal 
source
Hp with Alteco 
endotoxin 
hemoadsorber 
(Alteco medical Ab, 
Sweden)
2 sessions of 2 h at 24-h 
interval
25% High
 Zheng 2017 China 20 Sepsis, severe sepsis, or septic shock Hp with Adsorba 300 
filter (manufac-
turer not reported)
1 Hp session of 2.5 h 80% Unclear
Hemofiltration
 Chung 2017 USA 37 Septic shock and burn CVVH nr 57% Unclear
 Cole 2002 nr 24 Severe sepsis with end-organ dysfunction 
or septic shock
CVVH with AN69 
Filtral 12 filter 
(Hospal, France)
1 session of 2 d 33% Unclear
 Guo 2017 China 22 Severe sepsis or septic shock CVVH with AN69 filter 1 session of 2 d 45% Unclear
 Han 2011 China 45 Severe sepsis CVVH with AN69 filter 1 session of 3 d 41% Unclear
 Jing 2015 China 97 Severe sepsis or septic shock CVVH 1 session of at least 3 d 37% High
(Continued)
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patients) found no difference (relative risk = 1.11 [95% CI, 





0.001). Similarly, when excluding trials performed in Japan 
by the Nakamura group (five trials and 162 overall patients), 
polymyxin B immobilized fiber column hemoperfusion 
was associated with no difference in mortality compared to 
conventional therapy (relative risk = 0.98 [95% CI, 0.86 to 
1.12], P = 0.80; Supplemental Digital Content, figs. S10-
S13, http://links.lww.com/ALN/B977).
Hemoperfusion with Other Devices. Hemoperfusion with 
devices other than polymyxin B–immobilized filter 
column (seven trials and 385 patients) was not associ-
ated with a difference in mortality compared to con-
ventional therapy (relative risk  =  0.81 [95% CI, 0.53 
to 1.21], P  =  0.30, very low-certainty evidence). The 
hemoperfusion devices included were Adsorba-300 filter 
(one trial, relative risk  =  0.50 [95% CI, 0.22 to 1.14], 
P  =  0.10); Alteco endotoxin hemoadsorber (one trial, 
relative risk = 0.57 [95% CI, 0.06 to 5.03], P = 0.61); 
CytoSorb (two trials, relative risk = 0.94 [95% CI, 0.14 
to 6.49], P  =  0.95); HA330 resin cartridge (two trials, 
relative risk = 0.61 [95% CI, 0.31 to 1.19], P = 0.15); 
and Matisse EN 500 endotoxin adsorber (one trial, 
relative risk  =  1.13 [95% CI, 0.66 to 1.96], P  =  0.65; 
Supplemental Digital Content, fig. S3, http://links.lww.
com/ALN/B977).
Hemofiltration techniques
The use of hemofiltration with a blood purification aim 

















 meng 2016 China 56 Septic shock and ArDS CVVH with AN69 filter 
(Gambro Industries, 
France)
1 session of 3 d 32% High
 payen 2009 France 76 Severe sepsis or septic shock CVVH with Duraflo 
II filter (edwards 
Lifesciences, USA)
1 session of at least 4 d 44% Unclear
 peng 2010 China 22 Severe sepsis CVVH with AN69 filter 1 session of 3 d 18% Unclear
 Quenot 2015 France 60 Septic shock CVVH 1 session of 2 d 48% High
 Sander 1997 Germany 26 Severe sepsis or septic shock CVVH with AN69 
multiflow 60 filter 
(Hospal, France)
1 session of at least 2 d 92% High
 Wang 2009 China 89 Septic shock CVVH 1 session of 7 d 17 Unclear
 Xu 2014 China 22 Sepsis and burn CVVHDF 1 session of 12 h 18% Unclear
 Zheng 2017 China 20 Sepsis, severe sepsis, or septic shock CVVH with m100 set 
(manufacturer not 
reported)
1 session of 24 h 80% Unclear
Combined hemofiltration and hemoperfusion
 Hassan 2013 malaysia 23 Severe sepsis or septic shock CpFA with DF-140 
(Infomed, 
Switzerland)
1 session of 24 h or until 
clinical improvement
83% High
 Livigni 2014 Italy 184 Septic shock CpFA with Lynda 
(bellco, Italy)
5 session of at least 10 h,  
in 5 consecutive days
49% Unclear
 peng 2005 China 20 Sepsis and burn CVVH with AN69 
multiflow-60 filter 
(manufacturer 
not reported) + 
pmX-Hp
nr 20% Unclear
 Zheng 2017 China 20 Sepsis, severe sepsis, or septic shock CVVH with m100 




1 CVVH-session of 24 h and 
1 Hp session of 2.5 h
80% Unclear
Plasmapheresis
 busund 2002 russia 106 Severe sepsis or septic shock na 2 sessions of about 2 h 
in 24 h
54% High
 reeves 1999 Australia 22 Severe sepsis na 1 session of 36 h 46% Unclear
ALI, acute lung injury; ArDS, acute respiratory distress syndrome; CVVH, continuous veno-venous hemofiltration; CVVHDF, continuous veno-venous hemodiafiltration; CpFA, coupled 
plasma filtration adsorption; Hp, hemoperfusion; mrSA, methicillin-resistant Staphylococcus aureus; pmX, polymyxin b–immobilized fiber column; na, not applicable; nr, not reported.
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(relative risk = 0.79 [95% CI, 0.63, 1.00], P = 0.05, trial 
sequential analysis inconclusive, very low-certainty evi-
dence) in 13 trials and 596 patients without acute kid-
ney injury requiring renal replacement therapy (fig. 3 and 
Supplemental Digital Content, fig. S14, http://links.lww.
com/ALN/B977). On subgroup analysis, hemofiltration 
was not associated with a difference in mortality in tri-
als conducted in Europe and the United States (relative 
risk = 0.94 [95% CI, 0.74 to 1.19], P = 0.61, I2 = 0%, 
five trials and 223 patients) but was associated with a 
decrease in mortality in trials conducted in Asia (relative 
risk = 0.58 [95% CI, 0.40 to 0.82], P = 0.002, I2 = 0%, 
eight trials and 373 patients; P
groups
 = 0.02); other analy-
ses are reported in the supplement (Supplemental Digital 
Content, figs. S15-S18, table S9 and eResults 2, http://
links.lww.com/ALN/B977).
Combined Hemofiltration and Hemoperfusion techniques
The association of hemoperfusion and hemofiltration was 
not associated with a significant difference in mortality 
compared to control (relative risk = 0.63 [95% CI, 0.36 to 
1.13], P = 0.12, trial sequential analysis inconclusive, very 
Fig. 2. Forest plot of the relative risk of mortality at longest follow up available with polymyxin b-immobilized fiber column hemoperfusion. 
Various subanalyses are also reported. m-H, mantel-Haenszel; pmX-Hp, polymyxin b immobilized fiber column hemoperfusion.
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low-certainty evidence) in four trials including a total of 
247 patients without acute kidney injury requiring renal 
replacement therapy (fig. 3).
plasmapheresis techniques
Plasmapheresis was associated with a lower mortality com-
pared to standard treatment (relative risk = 0.63 [95% CI, 
0.42 to 0.96], P = 0.03, trial sequential analysis inconclu-
sive, very low-certainty evidence) with two trials and 128 
patients included (fig. 3).
Discussion
We performed a comprehensive systematic review and 
meta-analysis on the mortality effects of blood purification 
with extracorporeal techniques in sepsis. The certainty of 
evidence underlying the use of blood purification therapies 
in sepsis is very low, and does not support their systematic 
use in patients with sepsis with or without septic shock.
Hemoperfusion
A variety of hemoperfusion techniques exists. Only a few 
randomized clinical trials were published on hemoper-
fusion techniques other than polymyxin B–immobilized 
filter column (e.g., CytoSorb, Alteco endotoxin hemoad-
sorber), suggesting the need for further clinical trials. 
However, polymyxin B immobilized fiber column hemo-
perfusion emerged as a promising therapy in septic shock 
with elevated endotoxin levels, and several studies were 
published on the topic in the past 20 yr. This technique 
consists of using a sorbent cartridge containing fibers 
coated with polymyxin B, an antibiotic with high affin-
ity for lipopolysaccharide.9 Lipopolysaccharide is a cell 
wall component in Gram-negative bacteria that acts as an 
endotoxin by stimulating the production of inflammatory 
mediators by macrophages in a dose-dependent way and 
enhancing the inflammatory response.9,64 Endotoxemia 
seems to be more pronounced when tissue hypoperfu-
sion is present and lipopolysaccharide blood levels seem 
to correlate with sepsis severity.9,65 Promising results in 
Fig. 3. Forest plot of the relative risk of mortality at the longest follow-up available with hemofiltration, combined hemofiltration and hemo-
perfusion, or plasmapheresis. blood purif., blood purification; m-H, mantel-Haenszel.
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pilot studies showed improvement in inflammatory medi-
ators,10 cardiac and renal dysfunction,56 hemodynam-
ics, organ dysfunction, and 28-day mortality30 in patients 
with abdominal septic shock. All these promising findings, 
together with the significant increase in arterial pressure 
after therapy initiation,15,17,30 made polymyxin B immobi-
lized fiber column hemoperfusion an attractive therapy for 
clinicians. Conversely, recent large high-quality trials such 
as the EUPHRATES (Evaluating the Use of Polymyxin 
B Hemoperfusion in a Randomized Controlled trial 
of Adults Treated for Endotoxemia and Septic Shock)17 
and the ABDO-MIX (Effects of Hemoperfusion With a 
Polymyxin B Membrane in Peritonitis With Septic Shock) 
group46 trials yielded inconclusive results and reported a 
nonsignificant increase in mortality with polymyxin B 
immobilized fiber column hemoperfusion at the longest 
follow-up assessed.
The EUPHRATES trial, which is the largest and high-
est-quality randomized clinical trial performed so far, 
randomized 450 patients with septic shock and a high endo-
toxin activity assay level to two sessions of polymyxin B 
immobilized fiber column hemoperfusion of 90 to 120 min 
at a 24 h distance or to a sham treatment aiming at reducing 
28-day mortality. The trial found no significant difference 
in the primary endpoint in the overall population or in the 
higher disease severity subgroup.17
Our meta-analysis including 13 trials on polymyxin B 
immobilized fiber column hemoperfusion is the largest and 
most comprehensive to date. Recently, some meta-analy-
ses14,15,66 on polymyxin B immobilized fiber column hemo-
perfusion have appeared but failed to include some old 
and new randomized clinical trials. A meta-analysis con-
cluded that this therapy may reduce mortality in patients 
with severe sepsis and septic shock in high disease severity 
subgroups based upon the aggregate analysis of 12 non-
randomized trials and 5 small randomized clinical tri-
als representing a very low-quality evidence.14 Two other 
meta-analyses respectively including only six and seven 
randomized clinical trials concluded that only low-quality 
evidence supported polymyxin B immobilized fiber col-
umn hemoperfusion for mortality reduction in sepsis.15,66 
Since the release of EUPHRATES and other trials, a more 
comprehensive analysis was made possible. The positive 
results previously reported regarding polymyxin B immo-
bilized fiber column hemoperfusion were driven by small 
randomized clinical trials conducted in Asia of low meth-
odologic quality. Interestingly, when limiting the analysis 
to trials published after 2010 and including the two larg-
est randomized clinical trials performed on the topic,17,46 
polymyxin B immobilized fiber column hemoperfusion is 
associated with a higher mortality rate at the longest fol-
low-up available. This together with inconclusive results on 
trial sequential analysis suggests that the current aggregate 
randomized evidence cannot consistently refute potential 
positive or detrimental effects on mortality. These findings 
do not support the use of polymyxin B immobilized fiber 
column hemoperfusion in sepsis and septic shock.
Hemofiltration
The use of hemofiltration techniques as a blood purification 
treatment in patients without renal failure has also been sug-
gested, with controversial results and insufficient evidence 
to recommend its use outside of experimental clinical set-
tings.16,67 High-volume hemofiltration, further increasing 
plasma exchanges, was also investigated with limited results 
in patients with or without renal failure.29,68 We found a pos-
itive survival trend associated to hemofiltration, although 
those results are driven by small, low-quality randomized 
trials, and further investigation is therefore warranted.
plasmapheresis
The first randomized clinical trial to ever address plas-
mapheresis as a blood purification technique reported a 
decrease in the intensity of acute-phase response.50 A sec-
ond randomized clinical trial with a larger sample popula-
tion found an absolute mortality risk reduction of 20.5%.28 
Despite those promising results, the evidence is still too 
weak to recommend the use of plasmapheresis for blood 
purification in sepsis.69
Disease Severity
Previous meta-analyses found that hemoperfusion was 
associated with a large positive effect in trials with a con-
trol group mortality rate greater than 60%, suggesting that 
hemoperfusion could be useful in the setting of higher 
disease severity.14,66 Our study yielded similar findings and 
also found a trend toward increased mortality in the lower 
disease severity subgroup (mortality less than 30%). Meta-
regressions on APACHE II and sepsis-related organ failure 
assessment scores, both predictors of sepsis mortality, did 
not find any significant trend supporting those findings. 
Furthermore, most trials with a greater than 60% control 
group mortality are at unclear/high risk of bias, are small in 
size, and were conducted in Asia. In the EUPHRATES trial, 
the per-protocol subgroup analysis with high disease sever-
ity, including patients with a Multiple Organ Dysfunction 
Score greater than 9 at randomization and a control group 
1-year mortality rate of 50%, was inconclusive and did not 
suggest any trend favoring polymyxin B immobilized fiber 
column hemoperfusion.17
Those inconsistencies make a beneficial effect of hemo-
perfusion or polymyxin B immobilized fiber column 
hemoperfusion in high-disease-severity patients unlikely. 
This specific question merits further investigation.
Future Directions
Current randomized evidence cannot support the use 
of extracorporeal blood purification techniques; further 
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trials are warranted before systemic implementation of 
these techniques. Furthermore, an increase in mortality 
related to extracorporeal therapies should not be excluded. 
Some randomized clinical trials describe a trend toward 
higher mortality with polymyxin B immobilized fiber 
column hemoperfusion46 or CytoSorb-HP54, for exam-
ple. Numerically higher adverse events with polymyxin B 
immobilized fiber column hemoperfusion17,46 and greater 
disease severity with hemofiltration45 were also reported. 
Our meta-analysis found an increased mortality at the lon-
gest follow-up available with polymyxin B immobilized 
fiber column hemoperfusion in a post hoc subgroup analysis 
including only the trials published after 2010. The unspecific 
removal of cytokines may remove mediators necessary to 
the function of the immune system, eventually provoking 
a deleterious outcome. Furthermore, the complex inter-
action between extracorporeal devices and inflammatory 
systems, micronutrients,70 trace elements, electrolytes, and 
antibiotics levels and activity remain uninvestigated. Only 
few studies assessed the impact of those therapies on anti-
biotics, the only proven therapy in sepsis. A recent study 
on in vitro removal of antiinfective agents by CytoSorb-HP 
showed that all tested antibiotics were adsorbed by the car-
tridge in substantial amounts.71 The authors speculated that 
an additional dose within the first hours of treatment and 
therapeutic drug monitoring should be considered in this 
population.71 Similarly, an in vitro study assessing the effects 
of polymyxin B immobilized fiber column hemoperfusion 
on nine antibiotics reported adsorption of linezolid, sug-
gesting a necessity for the monitoring of blood antimicro-
bial concentrations during polymyxin B immobilized fiber 
column hemoperfusion.72,73 A larger literature is present on 
hemofiltration, suggesting an increased antibiotic clearance 
with these devices.74–76
Strengths and Limitations
We performed a comprehensive meta-analysis on blood 
purification techniques in sepsis and septic shock, which 
represents an important update to the literature in compar-
ison to previous meta-analyses.13–16 Limitations of this study 
may appear similar to those of previous meta-analyses. Most 
included studies are small in size and at unclear or high risk 
of bias. Some studies assessed technical feasibility, but side 
effects were rarely reported, and a systematic assessment of 
adverse events is warranted in future trials. Heterogeneity 
in sepsis management, blood purification regimens (e.g., 
modality, hemofiltration volume, duration of the session, 
filter and cartridge change, and so forth), and populations 
across different centers is evident, but we made an attempt 
at an exploration through several subanalyses in order to 
further assess the clinical potential of blood purification 
modalities in sepsis. The positive treatment effect found in 
trials conducted in Asia was also reported elsewhere13 and 
could be explained by publication bias, small studies effect, 
low methodologic quality, or a higher burden of disease as 
suggested by the high control group mortality. Furthermore, 
seven polymyxin B immobilized fiber column hemoperfu-
sion trials from Japan were performed before 2005, and the 
progress in conventional therapy management and outcome 
in the past years could have diluted or cancelled the bene-
ficial effects of this treatment.
Conclusions
Very low-quality randomized evidence demonstrates that 
the use of hemoperfusion, hemofiltration, or plasmapheresis 
may reduce mortality in sepsis or septic shock. Moderate-
certainty evidence supports that polymyxin B immobilized 
fiber column hemoperfusion is not associated with any sig-
nificant difference in mortality in comparison to conven-
tional treatment regimen. Detrimental effects on survival 
could not be excluded by aggregate randomized evidence. 
Further high-quality randomized controlled trials ade-
quately powered for mortality are needed to assess the real 
impact of blood purification techniques before such thera-
pies can be systematically implemented in clinical practice.
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